Clinical research of Shuweifang on treating patients with chronic atrophic gastritis

[Objective] To observe the efficacy and safety of Shuweifang on the treatment of CAG.[Methods]Eightyone patients with CAG were divided into two groups in a randomized and appositive drug-controlled clinical trail.Forty one cases in the treatment group were treated with CAG and forty cases in the control group were treated with Weifuchun.The change of clinical symptom was observed.Atrophy of glandular organ in gastric mucosa,intestinal metaplasia(IM),atypical hyperplasia(ATP) and helicobacter pyloric infection were observed by gastroscope and biopsy of gastric mucosa.[Results]The total effective rate of Shuweifang group and Weifuchun group in improving pathological changes were 75.61% and 50.00% respectively.There was a significantly statistical difference between the two groups(P0.05).The total effective rate of the treatment group and the control group in ameliorating symptoms were 95.12% and 47.50%.The statistics results showed significant difference between the two groups(P0.01).Neither serious side effects nor cancerous lesion of CAG were found during the processes of clinical therapy.[Conclusion ]Shuweifang greatly improves the clinical symptoms and gastric mucosa pathology of patients with CAG,IM and ATP,and improved effectively recoverable quality of morphology of glandular organ in gastric mucosa of CAG.